



Special article

[Translated article] OrPhar-SEFH 2024–2027 Strategic Plan



Mónica Climente Martí^{a,*}, María Dolores Edo Solsona^b, María Reyes Abad Sazatornil^c,
María Pilar Bachiller Cacho^d, Sergio Fernández Espinola^e, Paula Guijarro Martínez^f, Elena Gras Colomer^g,
Alicia Herrero Ambrosio^h, Silvia Manrique Rodríguezⁱ, Isabel Martín Herranz^j,
José Manuel Martínez Sesmero^k and José Luis Poveda Andrés^l

^a Servicio de Farmacia, Hospital Universitario Dr. Peset, Valencia, Spain

^b Servicio de Farmacia, Hospital Universitari i Politècnic La Fe, Valencia, Spain

^c Servicio de Farmacia, Hospital Universitario Miguel Servet, Zaragoza, Spain

^d Servicio de Farmacia, Hospital Universitario Donostia, Donostia-San Sebastián, Spain

^e Servicio de Farmacia, Hospital de Antequera, Málaga, Spain

^f Servicio de Farmacia, Hospital Ramón y Cajal, Madrid, Spain

^g Dirección General de Farmacia, Generalitat Valenciana, Valencia, Spain

^h Servicio de Farmacia, Hospital Universitario La Paz, Madrid, Spain

ⁱ Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain

^j Servicio de Farmacia, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

^k Subdirección Médica, Hospital Clínico Lozano Blesa, Zaragoza, Spain

^l Gerencia, Hospital Universitari i Politècnic de la Fe, Valencia, Spain

ARTICLE INFO

Article history:

Received 23 December 2024

Accepted 3 March 2025

Available online 6 June 2025

Keywords:

Rare diseases

Orphan drugs

Strategic plan

Multi-criteria decision analysis

Interdisciplinary teams

A B S T R A C T

To promote the transformation of hospital pharmacy in the field of rare diseases, the OrPhar-SEFH Strategic Plan 2024–2027 was developed. Twelve hospital pharmacists from the OrPhar-SEFH group participated in the project which was developed in 3 phases: Situation analysis, trends, and current challenges in rare diseases and their impact on the role of hospital pharmacist through literature review, interviews with hospital pharmacists and patients (FundAME and Fedhemo), and SWOT analysis; Definition of lines of action grouped into five strategic axes AEIOU (Alliances, Evidence, Research/Innovation, Optimization, and Union); and Prioritization of lines of action based on impact and feasibility. In order to achieve this, the existing trends and barriers in the field of rare diseases and hospital pharmacy were identified and classified around 4 levers for change: transformation of the care process, patient experience, evaluation and access to orphan drugs, and real-world evidence. The SWOT analysis identified key success factors, and interviews with patients identified their needs in four pillars: role of the hospital pharmacist, patient experience, patient education, and access to treatment. A total of 23 lines of action were agreed upon: Alliances (6), Evidence (3), Research/Innovation (4), Optimization (7), and Union (3). Based on their impact and feasibility, the following were prioritized: promoting hospital pharmacist collaboration in decision-making structures regarding the evaluation and positioning of orphan drugs, enhancing the role of hospital pharmacist in the critical analysis of scientific evidence in rare diseases and its translation to interdisciplinary clinical teams, encouraging the use of Multi-Criteria Decision Analysis methodology in orphan drugs, promoting the integration of hospital pharmacist into interdisciplinary teams managing patients with rare diseases, and creating a network of specialized hospital pharmacist services in rare diseases. Ultimately, the OrPhar-SEFH Strategic Plan 2024–2027 defines the roadmap to enhance the role of hospital pharmacist in addressing rare diseases, improving access and evaluation of orphan drugs, and optimizing the care process to improve health outcomes, quality of life, and patient experience.

© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H.). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

DOI of original article: <https://doi.org/10.1016/j.farma.2025.03.001>.

* Corresponding author.

<https://doi.org/10.1016/j.farma.2025.05.004>

1130-6343/© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H.). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Plan Estratégico OrPhar-SEFH 2024–2027

R E S U M E N

Palabras clave:

Enfermedades raras
Medicamentos huérfanos
Plan estratégico
Análisis de decisión multicriterio
Equipos interdisciplinarios

Con el objetivo de impulsar la transformación de la farmacia hospitalaria en el ámbito de las enfermedades raras, se llevó a cabo el desarrollo del Plan Estratégico OrPhar-SEFH 2024–2027. Participaron en el proyecto los 12 farmacéuticos de hospital del grupo OrPhar-SEFH y se desarrolló en 3 fases: Análisis de situación, tendencias y retos actuales en enfermedades raras y su impacto en el rol del farmacéutico de hospital mediante búsqueda bibliográfica, entrevistas a farmacéuticos de hospital y pacientes (FundAME y Fedhemo) y realización de análisis DAFO; Definición de líneas de acción agrupadas en 5 ejes estratégicos AEIOU (Alianzas, Evidencia, Investigación/Innovación, Optimización y Unión); y Priorización de líneas de acción según impacto y factibilidad. En la consecución de este, se identificaron las tendencias y barreras existentes en el ámbito de las enfermedades raras y la farmacia hospitalaria y se clasificaron en torno a 4 palancas de cambio: transformación del proceso asistencial, experiencia del paciente, evaluación y acceso de medicamentos huérfanos y evidencia en vida real. El análisis DAFO identificó los factores claves de éxito y las entrevistas con pacientes identificaron sus necesidades en 4 pilares: rol del farmacéutico de hospital, experiencia del paciente, educación del paciente y acceso al tratamiento. Se consensuaron un total de 23 líneas de acción: Alianzas (6), Evidencia (3), Investigación/Innovación (4), Optimización (7) y Unión (3). Según su impacto y factibilidad se priorizaron: fomentar la colaboración del farmacéutico de hospital en las estructuras de decisión sobre evaluación y posicionamiento de medicamentos huérfanos, potenciar el papel del farmacéutico de hospital en el análisis crítico de la evidencia científica en enfermedades raras y su traslación a los equipos clínicos interdisciplinarios, fomentar el uso de la metodología de análisis de decisión multicriterio en medicamentos huérfanos, impulsar la integración del farmacéutico de hospital en los equipos interdisciplinarios de manejo de pacientes con enfermedades raras y crear una red de servicios de farmacéuticos de hospital especializados en enfermedades raras. En definitiva, el Plan Estratégico de OrPhar-SEFH 2024–2027 define la hoja de ruta para potenciar el papel del farmacéutico de hospital en el abordaje de enfermedades raras, mejorando el acceso y evaluación de medicamentos huérfanos y optimizando el proceso asistencial para mejorar los resultados en salud, la calidad de vida y la experiencia de los pacientes.

© 2025 Los Autores. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Farmacia Hospitalaria (S.E.F.H.). Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The care of patients with rare diseases (RDs) or minority diseases is an ongoing challenge for health systems, due to their special characteristics (clinical complexity and care, social and financial costs). In Europe, RDs have been defined as those with a prevalence of less than 5 cases per 10,000 inhabitants.¹ Currently, more than 7000 RDs have been identified. These are generally characterised as inherited diseases that often manifest in childhood, are chronic and degenerative, and cause high morbidity, mortality, and pronounced disability. They significantly affect the quality of life of patients and their families.^{2,3}

It is estimated that RDs affect between 6% and 8% of the European population (i.e. between 24 and 36 million people, 3 million of whom live in Spain). A report by the Gaspar Casal Foundation entitled “*Las Enfermedades Raras en España: estado de situación y oportunidades de transformación en el nuevo contexto digital*” estimated that around 12 million people in Spain live with RDs, either because they or a family member has one.⁴

The approach to RDs is highly complex regarding aetiology, diagnosis, prognosis, and treatment. Patients usually wait an average of 4 years for a correct diagnosis, and in 20% of cases, diagnosis is delayed by 10 years or more.⁵ To address these diseases from a holistic and multidimensional perspective,⁵ patient follow-up generally requires multidisciplinary care, the use of supportive therapies, medical devices, support services (rehabilitation, mental health), and educational and social resources.⁵

Therapeutic innovation in the field of RDs is also a major challenge. Medicines developed to address unmet medical needs in RDs, known as orphan drugs (ODs), are often supported by limited scientific evidence of efficacy and safety at the time of marketing. The clinical trials conducted often have significant methodological limitations, including small and heterogeneous patient populations, a lack of valid therapeutic comparators, reliance on surrogate endpoints to assess clinical efficacy, and short follow-up periods. As a result, there are many uncertainties in decision-making that affect both access to and the funding of drugs and their use in clinical practice. In addition, the high cost of such medicines

—due to the complexity of their development, often involving advanced therapies, and the small target population for which they are intended—is having a growing economic impact on healthcare systems that impacts their sustainability. In 2021, expenditure on ODs was approximately €1 billion, representing 5.5% of total expenditure on medicines in the Spanish health system.⁶

In this context, the OrPhar-SEFH group was established in recognition of the many challenges that the management of ODs and RDs poses to health professionals, the health system, patients, and society as a whole. This group is part of the Spanish Society of Hospital Pharmacy (SEFH) and comprises hospital pharmacists (HPs) specialising in RDs. Its mission is to help improve the management and treatment of RDs by promoting the active involvement of HPs, thereby adding value to the entire patient care process and aiming to improve both health outcomes and the overall experience of patients with RDs.

Since its creation, the OrPhar-SEFH group has led innovative projects with a patient-centred approach that have contributed significantly to progress in the field of RDs. These include the biannual dissemination of Horizon Scanning Reports on ODs (available on the group's website⁷), the application of multi-criteria decision analysis (MCDA) to the evaluation of ODs,⁸ the development of the Manual of Good Practices for the Humanisation of Pharmacy Services in the Care of Patients with RDs,⁹ and the publication of a Monograph on Hospital Pharmacy for Patients with RDs.¹⁰

The working group has recently developed its OrPhar-SEFH Strategic Plan 2024–2027 with the aim of continuing to drive the transformation of hospital pharmacy in the field of RDs. In line with the group's mission and vision, the plan aims to generate knowledge, strengthen the relationship between healthcare professionals and patients, and position itself as a leader in the treatment of RDs, all within a patient-centred approach.

Methods

The OrPhar-SEFH 2024–2027 Strategic Plan was designed and drafted between March and September 2023 by the 12 HPs that formed

the OrPhar-SEFH working group at that time, with the methodological support of a consultancy firm. A small coordinating group of 3 HPs was set up to organise the tasks through paired interviews, online group work sessions for deliberation and consensus, and individual exercises for reflection and prioritisation.

The project was developed in 3 stages: assessment of the state of the art in the management of patients with RDs by HPs; definition of strategic axes and lines of action; and prioritisation of lines of action.

The first stage analysed the current situation, trends, challenges, and strategies in the field of RDs and their impact on the role of HPs, both nationally and internationally. To this end, a literature search was conducted in Pubmed and on the websites of organisations related to RDs and hospital pharmacy,^{2,3,11,12} along with benchmarking the role of HPs in similar international or national organisations. The information obtained was complemented by the experience of HPs of the OrPhar-SEFH group through a round of paired interviews, as well as by the inclusion of the patient perspective via interviews with representatives of 2 patient associations—the Fundación Atrofia Muscular Espinal and the Federación Española de Hemofilia—addressing aspects related to diagnosis, treatment, patient education, follow-up, and quality of life. The analysis and structuring of the data collected enabled the development of a SWOT matrix, the determination of key success factors in the areas of impact, needs, actions, and infrastructure and organisation, as well as the identification of barriers and trends, which were categorised into 4 strategic levers: transformation of the care process; patient experience; evaluation and access to drugs; and real-world data (RWD).

The second stage defined the lines of action of the Strategic Plan around 5 strategic axes—Alliances, Evidence, Innovation/Research, Optimisation, and Union (AEIOU)—in line with the SEFH Strategic Plan.¹² The preliminary proposal drawn up by the coordinating group was discussed and agreed with the whole OrPhar-SEFH group during an online working session. For each line of action, an objective was defined along with indicators, professional profiles involved, required resources for implementation, main obstacles, and an action plan.

The third and final stage involved a prioritisation exercise that considered all the strategic lines within each axis to determine the most relevant and feasible actions to advance the identified strategic objectives. Prioritisation was based on 2 variables—the impact on managing RDs and ODs, and the feasibility of implementation—while taking into account the current situation of the OrPhar-SEFH group and the various professional profiles involved in the development of the lines of action. Thus, each member of the group assigned a score (1–10) to each line of action regarding its impact and feasibility. A score of 10 was reserved for actions that had the greatest impact and were the easiest to implement in terms of resources, time, and feasibility.

On the basis of all the information gathered, several documents were produced and are available on the OrPhar-SEFH group website: the final version of the OrPhar-SEFH Strategic Plan 2024–2027,¹³ an executive summary of the same,¹⁴ and an infographic highlighting the main data to facilitate its dissemination.¹⁵

Results

In stage 1, the situation and context analysis at both national and international levels identified trends and barriers in the field of RDs and hospital pharmacy, which were categorised into 4 levers of change (Table 1). This stage included a SWOT analysis, thereby identifying strengths, weaknesses, opportunities, and threats (Table 2); the key success factors were divided into the areas of impact, needs, actions, and infrastructure and organisation (Fig. 1).

From the outset, the Strategic Plan was designed to incorporate the voices of patients in relation to their current experiences, the difficulties they face in their daily lives, and their expectations of the role of HPs in the management of RDs. Patient needs were grouped into 4 main areas:

The role of HPs and pharmacy services, patient experience, patient education, and access to treatment (see Table 3).

Table 1

Trends identified in the field of rare diseases and hospital pharmacy.

<p>Transforming the care process</p> <ul style="list-style-type: none"> • Personalisation of treatments through pharmacokinetic and pharmacogenetic research • Encouraging public-private partnerships to ensure the transformation of the care process • Patient empowerment for disease management and decision making • Developing new care models using digital tools for patient tracking and monitoring • Decision-making and personalisation of clinical care based on health outcomes <p>Patient experience</p> <ul style="list-style-type: none"> • Development of new models of care based on telepharmacy and ICT to improve the quality of the pharmacotherapeutic process • Establishing new ways of working with patients for the humanisation of pharmaceutical care • Medical decision making and clinical case resolution through multidisciplinary committees • Development of patient and caregiver education and training to improve patient experience and adherence to treatment • Development of new management models based on integrating and applying PROMs and PREMs <p>Assessment and access to ODs</p> <ul style="list-style-type: none"> • Acceptance of flexibility in clinical evidence due to the low prevalence of RDs • Collaboration with patient associations to include patients' needs and expectations • Patient empowerment in medicines evaluation, research, and clinical trials • Acceleration of procedures to shorten the time required to evaluate ODs <p>Real-life evidence</p> <ul style="list-style-type: none"> • Identification of population subgroups and identification of new correlates • Predictive analytics and early diagnosis through technology and artificial intelligence • Stratification of patients, analysis of adherence to treatment, and identification of risks and poor prognosis • Assessment of drug efficacy, efficiency, and safety in real clinical practice • Identification of the added value of care through the use of PROMs and PREMs

RDs, rare diseases; ODs, orphan drugs; PROM, patient-reported outcome measures; PREM, patient-reported experience measures; ICT, information and communication technologies.

Stage 2 defined the 23 lines of action of the Strategic Plan grouped around the 5 AEIOU strategic axes mentioned above. For each line of action, we defined an objective, indicators to evaluate implementation, the profiles of involved staff, necessary resources, obstacles to overcome, and an action plan. The goal was to implement the proposed lines of action, thereby laying the foundations for a new approach to RDs within the field of hospital pharmacy. Detailed information on the 23 lines of action can be consulted in the full Strategic Plan document available on the OrPhar-SEFH group website.¹³

In Stage 3, the lines of action of the Strategic Plan were prioritised based on their impact on addressing RDs and their feasibility of implementation. Table 4 shows the prioritisation by each strategic axis, and Fig. 2 shows the scores for the 23 lines of action based on their impact and feasibility.

Discussion

The OrPhar-SEFH Strategic Plan 2024–2027 provides a comprehensive and innovative vision for the approach to RDs. It has been developed with a scientific and strategic focus, applying a participatory working methodology that includes the perspective of professionals and patients. Thus, this plan defines and prioritises a total of 23 lines of action to be implemented by the working group over the period 2024–2027. It will strengthen the role of HPs in the care of patients with RDs, with the aim of addressing the challenges posed by ODs and RDs for the Spanish health system.

The analysis of the current situation, trends, challenges, and existing strategies in the management of RDs, both nationally and internationally, reveals a healthcare model showing signs of exhaustion and inefficiency, as well as a healthcare ecosystem that is constantly facing new challenges and including more stakeholders involved in the approach to RDs.¹⁶ We are clearly in a key transitional period driven by many

Table 2
SWOT matrix.

<p>Weaknesses</p> <ul style="list-style-type: none"> • Coordination and communication: fragmentation and lack of communication between the different working groups • Lack of knowledge of resources: group members' lack of knowledge of available resources and initiatives led by SEFH and OrPhar-SEFH • Data recording: the criteria for recording RWD are heterogeneous. Moreover, there is no shared database that collects information on patients with RDs, ODs, or resources of hospitals to which the members of the OrPhar-SEFH group belong • Positioning: low national and international visibility of the group at the level of pharmacy, patients, and scientific societies • Training: lack of training in rare diseases, genetics, positioning criteria and drug evaluation, RWD recording and analysis • Lack of visibility of HPs to patients: this could be improved by implementing cross-sectional patient follow-up throughout the care process • Partnerships: a lack of contact and information exchange with research institutes, universities, public health bodies, patient associations, and scientific societies • Drug evaluation: little collaboration between hospital pharmacy services and the SEFH, the Ministry of Health, and international HP bodies to work together on drug evaluation • Patients: lack of outreach and direct attention by the group to patients with RDs, in terms of care, support, and training on the appropriate treatments and care for their disease <p>Threats</p> <ul style="list-style-type: none"> • Social media: lack of social media presence may limit the group's ability to disseminate information, interact with other professionals and patients, and grow in visibility • Decentralisation: the transfer of health competences to the ACs may generate discrepancies in health regulations between them and affect the availability of resources for RDs in some regions • Political and social instability: political instability can affect funding and resources available for research and treatment of RDs, while social instability can affect patient quality of life and access to care • Genetic testing: coverage and availability of genetic testing vary by region, which can limit access to accurate diagnosis and appropriate treatment for patients with RDs • Spanish Health System: the lack of adaptation of the Spanish health system to new innovative medicines for RDs, together with the lack of additional budget allocation for their integration, limits patient access to ODs • Increasing numbers of patients with RDs: Increased awareness and knowledge about RDs means that more people are seeking medical care and receiving a diagnosis. This may increase the demand for specialised resources and treatments, which can be a challenge for health systems and ultimately for the group <p>Strengths</p> <ul style="list-style-type: none"> • Expertise: leading professionals in RDs with relevant roles and extensive experience in the management of patients with RDs and in drug evaluation • Specialist knowledge: the group's professionals are highly specialised in RDs and in effective treatment and care strategies for patients with RDs • Networking: OrPhar-SEFH has an extensive network of contacts within the medical and scientific community for knowledge exchange and joint projects • Alignment within the group: members share a common approach to promoting PROMs and PREMs, pharmacokinetics, pharmacogenetics, telepharmacy, and a willingness to change and improve through the new Strategic Plan • Access to resources: access to a wide range of resources from member hospitals, such as information on large numbers of patients, therapeutic options, diagnostic technologies, and databases • Geographical diversity: broad perspective on the specific needs and challenges of each region, as members work in different hospitals across Spain • Best practices: multiple best practices in hospital pharmacy services and the management of patients with RDs that could be scaled up and implemented across participating hospitals (e.g. monographic consultations and RD groups within pharmacy committees) <p>Opportunities</p> <ul style="list-style-type: none"> • Raising awareness of RDs: to promote awareness and understanding of RDs among patients and society via the group • Knowledge transfer: leveraging OrPhar-SEFH's position to transfer knowledge to hospital pharmacy services, other levels of care involved in the management of patients with RDs, and to patients • Communication: increase the group's digital and media presence as a strategic positioning tool for hospital pharmacy and RDs • Innovation: employ innovation to drive change in all areas (e.g. use of pharmacogenetics and pharmacokinetics, new funding models, use of disruptive technologies in clinical practice, research, and RWD) • Partnerships: collaboration with industry in the development of new solutions • Interdisciplinary approaches: improve cross-functional collaboration and communication between OrPhar-SEFH working groups, fostering communication and knowledge sharing (e.g. platform for sharing knowledge, best practices, data, and processes) • New projects: promote the development of larger-scale projects from OrPhar-SEFH that can have a positive impact on the management of patients with RDs (e.g. protocols for referral to reference hospitals, development of specific PROMs and PREMs, and standardisation of data collection)
--

ACs, autonomous communities; RDs, rare diseases; SWOT, strengths, weaknesses, opportunities, threats; ODs, orphan drugs; Orphar-SEFH, Rare Diseases and Orphan Drugs Group of the Spanish Society of Hospital Pharmacy; PROM, patient-reported outcome measure; PREM, patient-reported experience measure; RWD: real-world data; SEFH, Spanish Society of Hospital Pharmacists; ICT: information and communication technology.

influences, including the post-COVID setting, regulatory pressures, economic instability, the search for system sustainability and efficiency, digital transformation, the need to listen to patients, and the development of innovative and transformative models of engagement and collaboration.¹⁷

For these reasons, the European Union (EU) has established a strategic aim to improve access to diagnosis, information, and healthcare for the approximately 36 million patients with RDs in Europe. It will promote the development of national RD plans and strategies, the establishment of European Reference Networks (ERNs), facilitate the definition, coding, and inventory of RDs (European Rare Disease Registry Platform, Orphanet), promote the designation and authorisation of ODs, support research and development projects (Horizon Europe 2020 Project, ERICA: European Rare disease research Coordination and support Action), and empower patient organisations.¹⁸

In line with EU efforts, there are also several international initiatives to improve access to ODs, such as the Australian Life Saving Drugs Programme,¹⁹ which reimburses non-cost-effective medicines outside of the standard drug funding scheme. Similarly, the UK NHS has established innovative pricing agreements with the pharmaceutical industry

to facilitate access to non-cost-effective treatments—40% of which are medicines for RDs. These agreements include simple discounts, caps on cumulative cost or quantity used per patient, and outcome-based payment models.²⁰ Other innovative experiences worth highlighting include the international social network PatientsLikeMe,²¹ an open online community designed to transform patient stories into data, which already tracks more than 2800 diseases, or the RareConnect platform,²² created by EURORDIS (Rare Disease Europe and Care4Rare Canada) to connect and empower patients with RDs and their caregivers worldwide.

There are similar initiatives in Spain, such as the establishment of CSURs (Centros, Servicios y Unidades de Referencia del Sistema Nacional de Salud), aimed at providing equitable coverage across Spain through multidisciplinary teams that ensure continuity of healthcare provision²³; the multidisciplinary platform ObserveMHe, focused on generating knowledge and information about ODs²⁴; and the Red ÚNICAS, a network of interconnected hospitals aimed at improving care for children with RDs through the implementation of a collaborative model that shortens diagnostic times facilitates research and access to the most advanced therapies.²⁵




Figure 1. Key success factors of the OrPhar-SEFH Strategic Plan 2024–2027. RDs, rare diseases; HP, hospital pharmacist; ODs, orphan drugs; OrPhar-SEFH, Rare Diseases and Orphan Drugs Group of the Spanish Society of Hospital Pharmacy; PROM, patient-reported outcome measure; PREM, patient-reported experience measure, RWD, real-world data.

In line with the EU strategic objectives for RDs and international experiences, the Strategic Plan has identified trends grouped around 4 main axes for change (see Table 1). In this context, OrPhar-SEFH has developed several initiatives, including the Horizon Scanning Project,⁷ the application of MCDA to assess the therapeutic value of ODs,⁸ and the pharmacy services humanisation project regarding the care of patients with RDs.⁹ Other contributions include teaching activities (e.g. the monograph on hospital pharmacy for patients with RDs¹⁰) and research efforts, such as the development of a population pharmacokinetic/pharmacodynamic model to individualise eculizumab therapy in adults with atypical haemolytic uraemic syndrome.²⁶

Table 3

Summary of patient needs in relation to hospital pharmacists, obtained through interviews with representatives of rare disease patient associations.

Role of hospital pharmacists and pharmacy services

- Have an HP specialising in RDs involved in the entire care process
- Adapt existing protocols to the patients' care needs
- Raise awareness of the need for healthcare and treatment processes that are adapted to the specific rhythms and needs of RDs and patients with RDs
- Protocolise the coordinated, multidisciplinary, and comprehensive approach to patients with RDs within hospitals and between hospitals in all ACs
- Ensure effective communication and alignment between all professionals (e.g. HPs, clinicians, and nurses) in the management of patients with RDs
- Incorporate the perspective of patients in decision-making

Patient experience

- Establish multidisciplinary consultations and streamline appointments into 1 or 2 days to minimise trips
- Establish a system of home medication delivery programmes for patients with reduced mobility or other challenges in travelling to the centre
- Collect drugs in hospitals in the patient's AC, avoiding long journeys (between cities or ACs)
- Adapt PROMs and PREMs for patients with RDs to capture the reality of RDs, and protocolise and homogenise the collection of the data obtained
- Implement a support service to deliver treatments to patients' homes (e.g. for patients with haemophilia)
- Improve the location of hospital pharmacy services for easier access by patients

Patient education

- Provide educational materials and patient education by HPs (e.g. on treatments, adverse effects, and treatment expectations)
- Establish face-to-face consultations with HPs for follow-up and patient education when necessary (e.g. change of treatment, dosage)
- Run workshops with patients with RDs to address concerns with the healthcare professionals involved in their specific condition
- Have an expert HP available to respond to questions or concerns (e.g. on the storage and transport of ODs)
- Establish a telephone link with the HP to respond to questions or concerns

Access to treatment

- Implement drug evaluation criteria adapted to RDs
- Ensure early access to ODs in hospitals for patients who have already been diagnosed and have clinician-approved treatment
- Streamline processing and approval of applications for treatment of RDs
- Raise awareness of the importance of drug access to help stabilise health and improve outcomes in chronic patients with RDs

ACs, autonomous communities; RD, rare disease; HP, hospital pharmacist; OD, orphan drug; PROM, patient-reported outcome measure; PREM, patient-reported experience measures.

It is also worth noting that the OrPhar-SEFH Strategic Plan has incorporated patient advocacy in relation to current experiences and expectations regarding the role of HPs in the management of RDs, following the current trends of patient empowerment and increased involvement in therapeutic decision-making.^{27–29}

This is reflected in the SWOT analysis (Table 2), which highlights several weaknesses: limited visibility of HPs among patients and scientific societies; insufficient collaboration and synergy with other scientific societies involved in RDs and among SEFH working groups; lack of shared registries on the use of ODs and RWD in RDs; gaps in RD-specific training; and limited engagement of HPs and the OrPhar-SEFH group with the decision-making bodies involved in OD evaluation and access, as well as with research institutes, universities, public health agencies, patient associations, and scientific societies. Among the strengths identified, we highlight the specialised knowledge and experience of the HPs of the OrPhar-SEFH group in caring for patients with RDs and the management of ODs, along with their extensive network of contacts with healthcare and research professionals, facilitating the development of collaborative projects. Having members from all regions of Spain provides a comprehensive view on the specific needs and challenges of each area, while facilitating the sharing and scaling of best practices across centres.

The main external threats identified include: the lack of presence and visibility on social media; the insufficient adaptation of the Spanish health system to innovative treatments for RDs; inequities in access to treatments and care models across the ACs; and political and social instability, which may affect the availability of key resources, such as

Table 4
Prioritisation of the 23 lines of action by strategic axis.

Prioritisation	Description
Strategic axis – Partnerships	
A2	Identify RD patient associations to establish alliances and a communication channel to enable HP services to support patients and identify their needs
A5	To develop collaborative projects with the pharmaceutical industry aimed at developing innovative solutions in the setting of RDs
A1	Encourage the collaboration of HPs specialised in RDs in decision-making structures on the evaluation and positioning of ODs
A4	Identify leading universities, research centres, and institutes, and define collaborative plans to conduct technological and multidisciplinary research projects on RDs
A3	Define a collaboration plan with other scientific societies specialised in different RDs
A6	Implement communication channels and specific training plans for community pharmacy, primary care, socio-health, case managers, etc.
Strategic axis – Evidence	
E3	Promote research projects on ODs and RDs to obtain empirical data and evidence
E1	To strengthen the role of HPs in the critical analysis of scientific evidence on RDs and knowledge transfer to interdisciplinary clinical teams
E2	Encourage the participation of HPs in the use of PROMs and PREMs in the management and decision-making of RDs
Strategic axis - Innovation/Research	
I1	Promote the use of multi-criteria decision analysis for ODs
I4	Facilitate the implementation of innovative funding models and value-based public procurement
I3	Encourage the dissemination of calls for research on RDs and the participation of OrPhar-SEFH in these calls
I2	Identify existing AI tools and analyse their application in the area of RDs and hospital pharmacy
Strategic axis – Optimisation	
O4	Update and maintain the content of the OrPhar-SEFH website, including the most prevalent diseases and keeping records of the most commonly used ODs
O1	Promote the integration of HPs in interdisciplinary teams for the management of patients with RDs
O2	Implement and certify the OrPhar-SEFH Humanisation Plan
O6	Promote a new edition of the OrPhar-SEFH continuing professional development course that includes the latest evidence on the management and treatment of patients with RDs
O7	Developing telepharmacy and home delivery strategies
O3	Developing new communication channels with patients
O5	Stratify patients with RDs based on their characteristics and tailor their treatment for personalised pharmaceutical care
Strategic axis – Union	
U1	Create a network of HP services specialising in RDs
U2	Hold an annual conference on RDs and ODs to raise awareness of the role of HPs and OrPhar-SEFH in the care of patients with RDs
U3	Collaborate to create consistent messaging on the collection and disposal of drugs and drug administration devices dispensed in outpatient pharmacy care units

RD, rare disease; HP, hospital pharmacist; OD, orphan drug; Orphar-SEFH, Rare Diseases and Orphan Drugs Group of the Spanish Society of Hospital Pharmacy; PROM, patient-reported outcome measure; PREM, patient-reported experience measure.

timely diagnosis, early treatment, and the growing demand for specialised resources and treatments. The opportunities identified include the growing public awareness of RDs; the availability of digital and training resources provided by the SEFH; and the use of innovation as a driver of change across all levels, such as pharmacogenetics, pharmacokinetics, new funding models, and the integration of disruptive technologies into clinical practice, research, and RWD. Other opportunities include collaboration with the pharmaceutical industry in research and innovation; the intermediary role of HPs across specialised and nonspecialised care levels; and a focus on outcomes, including the use of PROMs and PREMs, which are already implemented in other disease areas and could be adapted to the RD setting.

Based on this analysis, and considering the key success factors identified in Fig. 1, a consensus was reached on 23 lines of action, which aim to foster collaborative work between HPs, professionals involved in the management of RDs, and patients, promote the healthcare role of HPs, guarantee equity in health care, and improve the quality of life of patients with RDs.

In this context, the 6 lines of action outlined under the strategic axis of alliances reflect the commitment of HPs to RDs, as demonstrated by numerous initiatives across healthcare,³⁰ education,^{24,31} and research.^{32–34} They also underscore the need to establish and strengthen alliances with external stakeholders—such as regulatory agencies, scientific societies, healthcare professionals, the Ministry of Health, regional authorities, universities, the pharmaceutical industry, research institutes, and patient associations—with the aim of fostering synergies and promoting knowledge exchange and collaboration. It is also worth noting the emergence of new stakeholders, such as start-ups and tech giants, which can join forces with HPs to promote integration and participation in patient monitoring, foster collaboration in research and innovation, and ultimately contribute to a comprehensive and multidisciplinary approach to patients with RDs.^{35,36}

The 3 lines of action defined under the strategic axis of evidence aim to promote critical analysis of existing scientific studies on ODs and

encourage participation in protocol development, with the goal of integrating the best available evidence. In parallel, they seek to foster the generation of new evidence and ensure personalised, patient-centred care that takes into account patients' needs and experiences.^{37–39}

The 4 lines of action under the proposed research/innovation axis aim to actively promote scientific research and the use of innovative funding models and evaluation criteria for ODs, going beyond traditional parameters such as efficacy, safety, and cost. They seek to incorporate assessment criteria that capture the therapeutic and social value of ODs from a holistic perspective that considers the needs of patients and the health system.^{40–47}

The fourth axis, optimisation, contains 7 lines of action aimed at ensuring the full participation of HPs in the entire healthcare process, as well as continuous communication and coordination with patients and the professionals involved. These actions also seek to promote the incorporation of new technologies and to support and raise awareness of existing initiatives within OrPhar-SEFH.^{48–52}

Finally, the fifth strategic axis is based on union and integrated, collaborative work in hospital and community settings. It proposes 3 lines of action with the aim of positioning HPs as key players in the treatment of RDs. It aims to increase their visibility to patients and other professionals, and promoting the use of sustainable practices that contribute to environmental care.^{53–55}

The prioritisation of lines of action identifies key initiatives that should be initiated or sustained within each strategic axis, based on their impact and feasibility of implementation. This approach aims to ensure the continuity of ongoing projects and to guide future projects envisaged by the working group.

Finally, the OrPhar-SEFH Strategic Plan, designed for implementation during the period 2024–2027, aims to support HPs in addressing the key challenges in the care of patients with RDs from the perspective of hospital pharmacy. It seeks to improve access to therapeutic innovations that deliver value to both patients and the healthcare system, develop a comprehensive and interdisciplinary care model for patients



Figure 2. Prioritisation of the 23 lines of action by strategic axis based on impact and feasibility.

with RDs, and adopt a holistic and multidimensional approach that facilitates knowledge sharing among professionals. The plan also emphasises the creation of individualised therapeutic and follow-up plans tailored to both the clinical and social health needs of each patient, as well as the involvement of patients and broader society in decision-making processes at various levels.

In summary, the Strategic Plan is intended to provide a roadmap for enhancing the role of hospital pharmacy in the management of RDs, improving access to and evaluation of ODs, and optimising the integrated and interdisciplinary care process to improve health outcomes, quality of life, and patient experience. In parallel, it aims to establish OrPhar-

SEFH as a reference body for the health system, healthcare professionals, and patients with RDs.

CRedit authorship contribution statement

Mónica Climente Martí: Writing – review & editing, Writing – original draft, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Sergio Fernández Espinola:** Conceptualization, Investigation, Methodology, Validation, Visualization. **Paula Guijarro Martínez:** Conceptualization, Investigation, Methodology, Validation, Visualization. **Elena**

Gras Colomer: Conceptualization, Data curation, Methodology, Project administration, Validation, Visualization. **Alicia Herrero Ambrosio:** Conceptualization, Investigation, Methodology, Supervision, Validation. **Silvia Manrique Rodríguez:** Conceptualization, Investigation, Methodology, Supervision, Validation. **Isabel Martín Herranz:** Conceptualization, Investigation, Methodology, Validation, Visualization.

Funding

None declared.

Acknowledgements

We would like to thank Deloitte Digital for their methodological support in the development of the Strategic Plan. The consulting work provided by Deloitte Digital was funded by Roche Farma.

References

- European Commission. Programme of community action on rare diseases (1999–2003) [Monografía en internet]. Brussels: European Commission; 1999 [consultado 04 Sep 2024]. Disponible en: https://ec.europa.eu/health/archive/ph_overview/previous_programme/rare_diseases/raredis_wpgm99_en.pdf.
- Ministerio de Sanidad. Estrategia en Enfermedades Raras del Sistema Nacional de Salud aprobada por el Consejo Interterritorial del Sistema Nacional de Salud el 3 de junio de 2009. Madrid: Ministerio de Sanidad; 2009 [consultado 04 Sep 2024]. Disponible en: <https://www.sanidad.gob.es/areas/calidadAsistencial/estrategias/enfermedadesRaras/docs/enfermedadesRaras.pdf>.
- Ministerio de Sanidad. Estrategia en Enfermedades Raras del Sistema Nacional de Salud. Informe de evaluación y líneas prioritarias de actuación Ministerio de Sanidad 2024. Madrid: Ministerio de Sanidad; 2024 [consultado 04 Sep 2024]. Disponible en: https://www.sanidad.gob.es/areas/calidadAsistencial/estrategias/enfermedadesRaras/docs/Informe_EERR_pendiente_de_NIPO.pdf.
- Errea M. Las Enfermedades Raras en España: estado de situación y oportunidades de transformación en el nuevo contexto digital [Monografía en internet]. Madrid: Fundación Gaspar Casal; 2024 [consultado 04 Sep 2024]. Disponible en: <https://fundaciongasparcasal.org/wp-content/uploads/2024/02/20240223-Informe-EER-Version-Web.pdf>.
- Ministerio de Sanidad. Informe ReeR 2023. Situación de las Enfermedades Raras en España [Monografía en internet]. Madrid: Ministerio de Sanidad; 2023 [consultado 04 Sep 2024]. Disponible en: https://www.sanidad.gob.es/areas/alertasEmergenciasSanitarias/vigilancia/docs/InformeEpidemiologicoAnual_2023_ACCESIBLE.pdf.
- Ministerio de Sanidad. Informe evolución de la financiación y fijación de precio de los medicamentos huérfanos en el SNS (2016–2021). Madrid: Ministerio de Sanidad; 2022 [consultado 04 Sep 2024]. Disponible en: https://www.sanidad.gob.es/areas/farmacia/publicaciones/informes/docs/202202222_Infor_Evol_Mtos_Huerfanos_SNS_2016_2021.pdf.
- Grupo OrPhar-SEFH. Proyectos del grupo OrPhar-SEFH. Informes horizon scanning [Monografía en internet]. Madrid: SEFH; 2022 [consultado 04 Sep 2024]. Disponible en: <https://gruposdetrabajo.sefh.es/orpharsefh/proyectos-del-grupo>.
- Grupo OrPhar-SEFH. Manual para el desarrollo de un informe de evaluación de medicamentos huérfanos por parte del grupo OrPhar-SEFH usando metodología de Análisis de Decisión Multicriterio [Monografía en internet]. Madrid: SEFH; 2022 [consultado 04 Sep 2024]. Disponible en: https://gruposdetrabajo.sefh.es/orpharsefh/images/stories/documentos/Manual_MCDA_OrPhar_SEFH_060520.pdf.
- Poveda Andrés JL, Company Albir MJ, Edo Solsona MD, Arasa Gastaldo E. Manual de buenas prácticas de humanización de los servicios de farmacia hospitalaria en la atención a pacientes con enfermedades raras. *newsRARE*. 2020;5(sup1):13–30.
- Edo Solsona MD, Company Albir MJ, Poveda Andrés JL. Farmacia hospitalaria para pacientes con enfermedades raras. 1ª ed. Valencia: LAIMPRENTACC; 2021.
- EURORDIS Rare Diseases Europe. Recommendations from the rare 2030 foresight study: the future of rare diseases starts today [Monografía en internet]. París: EURORDIS Rare Diseases Europe; 2021 [consultado 04 Sep 2024]. Disponible en: https://download2.eurordis.org/rare2030/Rare2030_recommendations.pdf.
- SEFH. Plan Estratégico de la Sociedad Española de Farmacia Hospitalaria 2023–2027 [Monografía en internet]. Madrid: SEFH; 2023 [consultado 04 Sep 2024]. Disponible en: https://www.sefh.es/sefhquien/Plan_Estrategico_Junta_2023-2027.pdf.
- OrPhar-SEFH. Plan estratégico OrPhar-SEFH 2024–2027 [Monografía en internet]. Madrid: SEFH; 2024 [consultado 04 Sep 2024]. Disponible en: https://gruposdetrabajo.sefh.es/orpharsefh/images/stories/documentos/Plan_Estrategico_OrPhar-SEFH_2024-2027.pdf.
- OrPhar-SEFH. Resumen ejecutivo del plan estratégico OrPhar-SEFH 2024–2027 [Monografía en internet]. Madrid: SEFH; 2024 [consultado 04 Sep 2024]. Disponible en: https://gruposdetrabajo.sefh.es/orpharsefh/images/stories/documentos/Resumen_Ejecutivo_PE_OrPhar-SEFH_2024-2027.pdf.
- OrPhar-SEFH. Infografía del Plan Estratégico OrPhar-SEFH 2024–2027 [Monografía en internet]. Madrid: SEFH; 2024 [consultado 04 Sep 2024]. Disponible en: https://gruposdetrabajo.sefh.es/orpharsefh/images/stories/documentos/Infografa_PE_OrPhar-SEFH_2024-2027.pdf.
- Wojtara M, Rana E, Rahman T, Khanna P, Singh H. Artificial intelligence in rare diseases diagnosis and treatment. *Clin Transl Sci*. 2023;16:2106–11. doi:10.1111/cts.13619.
- Ministerio de Sanidad. Estrategia de salud pública 2022. Mejorando la salud y el bienestar de la población [Monografía en internet]. Madrid: Ministerio de Sanidad; 2022 [consultado 04 Sep 2024]. Disponible en: https://www.sanidad.gob.es/ciudadanos/pdf/Estrategia_de_Salud_Publica_2022_Pendiente_de_NIPO.pdf.
- Comisión Europea. Contexto enfermedades raras en la union Europea [página web]. Bruselas: Comisión Europea; 2024 [consultado 04 Sep 2024]. Disponible en: https://health.ec.europa.eu/non-communicable-diseases/expert-group-public-health/rare-diseases_es#research-into-rare-diseases.
- Australian Government. Department of health and aged care. Life saving drugs program [página web]. Canberra Act: Department of Health and Aged Care; 2024 [consultado 04 Sep 2024]. Disponible en: <https://www.health.gov.au/our-work/life-saving-drugs-program>.
- National Institute for Health Care Excellence (NICE). Patient access schemes liaison unit [página web]. Manchester: National Institute for Health Care Excellence (NICE); 2024 [consultado 04 Sep 2024]. Disponible en: <https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit>.
- National Institute for Health Care Excellence (NICE). PatientsLikeMe [página web]. Manchester: National Institute for Health Care Excellence (NICE); 2019 [consultado 04 Sep 2024]. Disponible en: <https://www.patientslikeme.com>.
- National Institute for Health Care Excellence (NICE). RareConnect [página web]. Manchester: National Institute for Health Care Excellence (NICE); 2019 [consultado 04 Sep 2024]. Disponible en: <https://www.rareconnect.org/es>.
- Ministerio de Sanidad. Centros, Servicios y Unidades de Referencia del Sistema Nacional de Salud [página web]. Madrid: Ministerio de Sanidad; 2024 [consultado 04 Sep 2024]. Disponible en: <https://www.sanidad.gob.es/profesionales/CentrosDeReferencia/CentrosCSUR.htm>.
- Asociación para la Innovación en la Atención y los Cuidados a Pacientes con Enfermedades Raras (AINEERR). ObserveMHE: Observatorio de Medicamentos Huérfanos [página web]. Bilbao: AINEERR; 2024 [consultado 04 Sep 2024]. Disponible en: <https://observemhe.es/>.
- Hospital Sant Joan de Déu. Red ÚNICAS [página web]. Barcelona: Hospital Sant Joan de Déu; 2024 [consultado 04 Sep 2024]. Disponible en: <https://www.sjdhospitalbarcelona.org/es/hospital/proyectos-estrategicos/red-unicas-atencion-enfermedades-minoritarias>.
- Parra AP, Ramos N, Perurena-Prieto J, Manrique-Rodríguez S, Climente M, Quintanilla LG, et al. Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy. *Farm Hosp*. 2024;48(1):T16–22. doi:10.1016/j.farma.2023.09.009.
- Abdalla F, Zozaya N. El empoderamiento de los pacientes y su creciente incorporación en la toma de decisiones. *newsRARE*. 2020;5(2):6–18.
- Pérez-Ramos J, Abt-Sacks A, Perestelo-Pérez L, Rivero-Santana A, Toledo-Chávarri A, González N, et al. Shared decision making in rare diseases: an overview. *Rare Dis Orphan Drugs*. 2015;2(3):39–44.
- De Santis M, Hervas C, Weinman A, Bosi G, Bottarelli V. Patient empowerment of people living with rare diseases. Its contribution to sustainable and resilient healthcare systems. *Ann Ist Super Sanita*. 2019;55(3):283–91. doi:10.4415/ANN.19.03.15.
- Megías-Vericat JE, Monte-Boquet E, Martín-Cerezuela M, Cuéllar-Monreal MJ, Tarazona-Casany MV, Pérez-Huertas P, et al. Pilot evaluation of home delivery programme in haemophilia. *J Clin Pharm Ther*. 2018;43(6):822–8. doi:10.1111/jcpt.12718.
- Fundación KRONOS: Investigación clínica oncológica. Plataforma SingulaRES. Madrid: Doctaforum Servicios SL; 2024 [consultado 04 Sep 2024]. Disponible en: <http://www.enfermedades-singulares.com/public/profundiza-en-enfermedades-raras>.
- Gras-Colomer E, Mangas-Sanjuán V, Martínez-Gómez MA, Climente-Martí M, Merino-Sanjuán M. Quantitative assessment of the exposure-efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy. *Br J Clin Pharmacol*. 2022;88(6):2727–37. doi:10.1111/bcp.15198.
- Castro-Balado A, Bandín-Vilar E, Cuartero-Martínez A, García-Quintanilla L, Hermelo-Vidal G, García-Otero X, et al. Cysteamine eye drops in hyaluronic acid packaged in innovative single-dose systems: stability and ocular biopermanence. *Pharmaceutics*. 2022;14(10):2194. doi:10.3390/pharmaceutics14102194.
- Castro-Balado A, Cuartero-Martínez A, Pena-Verdeal H, Hermelo-Vidal G, Schmidt A, Montero B, et al. Cysteamine eye drops in hyaluronic acid packaged in innovative single-dose systems, Part II: long-term stability and clinical ocular biopermanence. *Pharmaceutics*. 2023;15(11):2589. doi:10.3390/pharmaceutics15112589.
- Zapotocka E, Batorova A, Bilic E, Boban A, Escuriola Ettingshausen C, Kotnik BF, et al. First experience of a hemophilia monitoring platform: florio HAEMO. *Res Pract Thromb Haemost*. 2022;6(2):e12685. doi:10.1002/rth2.12685.
- Pechmann A, König K, Bernert G, Schachtrup K, Schara U, Schorling D, et al. SMARTCARE – a platform to collect real-life outcome data of patients with spinal muscular atrophy. *Orphanet J Rare Dis*. 2019;14(1):18. doi:10.1186/s13023-019-0998-4.

37. Ruiz Millo O, Climente MM. Atención farmacéutica basada en la evidencia [Monografía en internet]. Madrid: SEFH; 2021 [consultado 04 Sep 2024]. Disponible en: [file:///C:/Users/maril/Downloads/art%3%ADculo-3-monograf%C3%ADA-1%20\(2\).pdf](file:///C:/Users/maril/Downloads/art%3%ADculo-3-monograf%C3%ADA-1%20(2).pdf).
38. Fernández-Llamazares CM, López-Briz E. Hospital pharmacist challenges in evaluation of scientific evidence and its incorporation to pharmacotherapeutic protocols through therapeutic committees in COVID-19 times. *Farm Hosp*. 2020;44(7):24–7. doi:10.7399/fh.11487. Erratum in: *Farm Hosp*. 2020;44(4):184. <https://doi.org/10.7399/fh.11540>.
39. Giraldo P, Camprodón M, Alcolea PC, Gras-Colomer E, Ibarretxe D, Lakhwani S, et al. Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain. *Med Clin (Barc)*. 2024;163(9):449–57. doi:10.1016/j.medcli.2024.06.006.
40. Edo-Solsona MD, Vitoria-Miñana I, Poveda-Andrés JL. Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases. *Farm Hosp*. 2020;44(1):10–5. doi:10.7399/fh.11262.
41. Grupo OrPhar-SEFH. Análisis de las evaluaciones de medicamentos huérfanos realizadas en España entre el 2018–2022 utilizando el Análisis de Decisión Multicriterio (MCDA) [Monografía en internet]. Madrid: SEFH; 2023 [consultado 04 Sep 2024]. Disponible en: <https://gruposdetrabajo.sefh.es/orpharsefh/images/MCDA-Orphar-SEFH-19dic23-FINAL.pdf>.
42. Gilabert-Perramon A, Torrent-Farnell J, Catalan A, Prat A, Fontanet M, Puig-Peiró R, et al. Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs. *Int J Technol Assess Health Care*. 2017;33(1):111–20. doi:10.1017/S0266462317000149.
43. de Andrés-Nogales F, Cruz E, Calleja MÁ, Delgado O, Gorgas MQ, Espín J, et al. FinMHU-MCDA Group. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study). *Orphanet J Rare Dis*. 2021;16(1):186. doi:10.1186/s13023-021-01809-1.
44. Blonda A, Denier Y, Huys I, Simoens S. How to value orphan drugs? A review of European value assessment frameworks. *Front Pharmacol*. 2021;12:631527. doi:10.3389/fphar.2021.631527.
45. Guarga L, Badia X, Obach M, Fontanet M, Prat A, Vallano A, et al. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut). *Orphanet J Rare Dis*. 2019;14(1):157. doi:10.1186/s13023-019-1121-6.
46. Schey C, Krabbe PF, Postma MJ, Connolly MP. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. *Orphanet J Rare Dis*. 2017;12(1):10. doi:10.1186/s13023-016-0555-3.
47. Lasalvia P, Prieto-Pinto L, Moreno M, Castrillón J, Romano G, Garzón-Orjuela N, et al. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review. *Expert Rev Pharmacoecon Outcomes Res*. 2019;19(4):409–20. doi:10.1080/14737167.2019.1633918.
48. Morillo-Verdugo R, Collado-Borell R, Arrondo-Velasco A, Domínguez-Cantero M, Fernández-Polo A, González-Corominas E, et al. Implementation of pharmaceutical care through telepharmacy: a guide for professionals and patients. *Farm Hosp*. 2022;46(7):115–22.
49. Barbadillo-Villanueva S, Áreas Del Aguila V, Robustillo-Cortés MLA, Gimeno-Gracia M, Sánchez Yáñez E, Hermenegildo-Caudevilla M, et al. Telematic interview in telepharmacy: a comprehensive guide for pharmacotherapeutic follow-up and informed drug delivery. *Farm Hosp*. 2024;48(4):T180–4. doi:10.1016/j.farma.2024.04.008.
50. Collado-Borrell R, Escudero-Vilaplana V, Narrillos-Moraza Á, Villanueva-Bueno C, Herranz-Alonso A, Sanjurjo-Sáez M. Patient-reported outcomes and mobile applications. A review of their impact on patients' health outcomes. *Farm Hosp*. 2022;46(3):173–81. doi:10.7399/fh.11830.
51. Grupo OrPhar-SEFH. Cuestionario de autoevaluación del grado de humanización de los servicios de farmacia hospitalaria en la atención a pacientes con enfermedades raras [página web]. Madrid: SEFH; 2024 [consultado 04 Sep 2024]. Disponible en: <https://farmaciaencuesta.live-website.com/>.
52. Company Albir MJ, Poveda Andrés JL, Edo Solsona MD. Presence of good humanization practices in the healthcare of patients with rare diseases in pharmacy services. *Farm Hosp*. 2024;48(1):3–8. doi:10.1016/j.farma.2023.06.013.
53. Ministerio de Sanidad. One Health [página web]. Madrid: Ministerio de Sanidad; 2024 [consultado 04 Sep 2024]. Disponible en: <https://www.sanidad.gob.es/areas/sanidadAmbiental/pesma/unaSolaSalud.htm>.
54. Lertxundi U, Orive G. Por una farmacia más sostenible. *Farm Hosp*. 2023;47(2):53–4. doi:10.1016/j.farma.2023.01.005.
55. SEFH. Proyecto 2023 +Sostenible [página web]. Madrid: SEFH; 2024 [consultado 04 Sep 2024]. Disponible en: <https://www.sefh.es/sostenible-proyecto.php>.